Leaders in Pharmaceutical Business Intelligence (LPBI) Group

New Concepts for Valuation of Portfolios of Intellectual Property Asset Classes: LPBI Group – A Case in Point

Author and Curator of own ideas and contents: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and of 2.0 LPBI Group

I acknowledge inputs to this article from:

Erich Greenbaum, the references to DAO and IP-NFT

Dr. Ofer Markman, comments on the Table

Prof. Stephen J. Williams, comments on the Table and on the applicability of IP-NFT concept to LPBI Group’s Portfolio of IP.

 

UPDATED on 4/7/2023

• Click on 1st Link for page 1
• Click on 2nd Link for page 2
• Click on Image of page 1
• Click on Image of page 2
• Adjust size to 200% page 1 and page 2

4-7-2023 – LPBI Portfolio of IP Valuation Aviva and SJW_p1

4-7-2023 – LPBI Portfolio of IP Valuation Aviva and SJW_p2

 

Updated on 2/25/2022 [ON HOLD, 3/2023]

We equate a major portion of LPBI Group’s Portfolio of  Intellectual Properties to have the potential to be #SNFT aka, SCIENTIFIC NON FUNGIBLE TOKENS: Examples

• one journal article of the curation type,
• one image in the gallery,
• one book: English or Spanish Edition
• one article in a book,
• one chapter of 10 articles in a book.
• one Series in the English Edition:

Series A, six volumes, cardiovascular

Series B, two volumes, Genomics 

Series C, two volumes, Cancer

Series D, four volumes, Immunology

Series E, four volumes, Precision Medicine

• one Series in the Spanish Edition: A,B,C,D,E

Series A, six volumes, cardiovascular

Series B, three volumes, Genomics 

Series C, two volumes, Cancer

Series D, four volumes, Immunology

Series E, four volumes, Precision Medicine

•  

We define smart contracts for dissemination of #SNFT as

the #liquidity of Scientific #knowledge

LPBI Group’s Portfolio of IP Assets as #SNFT include:

 

IP Asset Class I (+6K #SNFT)

• All the article curations in LPBI Group’s +6,100 scientific #articles in PharmaceuticalIntelligence.com

IP Asset Class II

• All electronic Table of Contents (eTOCs) of 18 Books in Medicine, aka BioMed e-Series

https://lnkd.in/ekWGNqA

• All eTOCs in Spanish Audio
• All eTOCs in Bi-Lingual English-Spanish Text
• All eTOCs in English Text

 

• All Cover Pages of 18 Books in Medicine – English Edition

IP Asset Class XII using inputs from IP Asset Class II

• All Cover Pages of 18 Books in Medicine – Spanish Translation by Series:

Series A: Cardiovascular – 6 volumes
Series B: Genomics – 2 volumes
Series C: Cancer – 2 volumes
Series D: Immunology – 4 volumes
Series E: Precision Medicine

• All Editorials of 18 Books – English Text
• All Editorials of 18 Books – English Audio

IP Asset Class V (+6K #SNFT)

• All Biological Images in Books, 18 volumes
• All Legends of images in Text format – considered for Text Analysis with Machine learning
• Gallery of Biological Images +6200
• Biological Images in Journal articles https://lnkd.in/eteNqpF not in Books

IP Asset Class XII – Part B of New Genre of Scientific Books

• Text Analysis with AI, Machine Learning – Natural Language Processing (NLP) Statistical & Deep Learning (DL) on

– Two books in Genomics
– Two books in Cancer & Oncology

• Graphic results of NLP and DL:

– Hypergraph Plots, one graph per Chapter and Expert interpretation text
– Tree Diagram Plots, one graph per Chapter and Expert interpretation text

 

IP Asset Class III

• 100 e-Proceedings of Biotech conferences

• 40 Tweet Collections of 40 of the 100 conferences

#oncology #biotech #medicine #ai #deeplearning #machinelearning #nlp #genomics #translation #graphic #hypergraph #cardiovascular #immunology #precisionmedicine #cancer #intellectualproperty

 

2.0 LPBI Missions

Four missions as LPBI’s exposition of the pipelines for 2021 -2025:

Mission #1:  NLP – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Statistical NLP and Deep Learning by Machine Learning using Wolfram Language for Biological Sciences

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

Mission #2:  Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph Databases – Content monetization infrastructure B2B and B2C.

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

Mission #3:  BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

Mission #4:  Synthetic Biology Software: Drug discovery Galectins

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

2.0 LPBI is a Very Unique Organization 

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and 2.0 LPBI, April 2012 to Present

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

LPBI Group’s Portfolio of 14 Intellectual Property Asset Classes

Two New Concepts in Valuation of IP Asset Classes: DAO and IP-NFT

Please review these two articles before reviewing the Table, below

What is a decentralized autonomous organization, and how does a DAO work?

https://cointelegraph.com/ethereum-for-beginners/what-is-a-decentralized-autonomous-organization-and-how-does-a-dao-work

 

IP-NFTs for Researchers: A New Biomedical Funding Paradigm

https://medium.com/molecule-blog/ip-nfts-for-researchers-a-new-biomedical-funding-paradigm-91312d8d92e6

https://medium.com/molecule-blog/ip-nfts-for-researchers-a-new-biomedical-funding-paradigm-91312d8d92e6

How do we see applicability of NFT to LPBI Group’s Intellectual Property Portfolio?

Data in tables updated on November 14, 2021

Data represent the views of LPBI Group’s Founder

For a detailed description of 1.0 LPBI Portfolio of IP Assets please review

1.0 LPBI 2012-2020 VISTA

https://pharmaceuticalintelligence.com/2019-vista/

For a detailed description of 2.0 LPBI Portfolio of IP Assets please review

2.0 LPBI 2021-2025 VISION

https://pharmaceuticalintelligence.com/vision/

In the Voice of Dr. Williams

See the columns under Dr. Williams Name

The reasoning will be discussed below but first the reader is directed to the two links: one a video and the second a blog on NFT Assets and Business Exits

Please View Video

https://www.youtube.com/embed/LU5Mv4TQEE8

The whole point of NFT is that the word “fungible” can also mean replacable so a non fungible asset cannot be replaced or even reproduced. Think of the Mona Lisa. It can be reproduced but not by the original artist so there is only one first nonfungible Mona Lisa.

This NFT concept works well in the art world but for assets you want to reproduce and sell over and over this concept is very poor and would not work well at all. It is a tempting idea for assests which may not have an ideal way to sell however most of LPBI assest are in fact, fungible.

 

Other related articles on this Open Access Online Scientific Journal to this topic include the following:

Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical & Life Sciences Research Categories, 10,440 Tags, Top Article 17,300 Views, Top Author 487,500 Views on PharmaceuticalIntelligence.com

Reporter: Aviva Lev-Ari, PhD, RN

Update on 7/1/2021 by Srinivas Sriram and Abhisar Anand

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

The Map of human proteins drawn by artificial intelligence and PROTAC (proteolysis targeting chimeras) Technology for Drug Discovery

Curators: Dr. Stephen J. Williams and Aviva Lev-Ari, PhD, RN

UPDATED on 11/5/2021

https://pharmaceuticalintelligence.com/2021/10/21/the-map-of-human-proteins-drawn-by-artificial-intelligence-and-protac-proteolysis-targeting-chimeras-technology-for-drug-discovery/

WORKFLOW for a Ten-Steps Medical Text Analysis Operation using NLP on LPBI Medical and Life Sciences Content

Author: Aviva Lev-Ari, PhD, RN with inputs related to Wolfram NLP Code by Madison Davis and Yash Choudhary

https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/